X4 Pharmaceuticals, Inc 8-K, filed Sep 11, 2020
X4 Pharmaceuticals, Inc (XFOR)
8-K
2020-09-11
For: 2020-09-11
View Original
Added on
April 12, 2026
About this 8-K
X4 Pharmaceuticals, Inc filed this 8-K on September 11, 2020.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | | ||||
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Data of earliest event reported): September 11, 2020
| (Exact name of registrant as specified in its charter) | ||||||||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(857 ) 529-8300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒
Item 8.01 Other Events
Dr. Renato Skerlj has tendered his resignation as Chief Scientific Officer of X4 Pharmaceuticals (the “Company”), effective at the close of business on October 2, 2020. Dr. Skerlj is leaving the Company to transition to become the President and CEO of a privately held biotechnology company. The Company thanks Dr. Skerlj for his service and the contributions he has made to the Company’s growth and development. The Company has commenced a search to identify a permanent replacement for Dr. Skerlj.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| X4 PHARMACEUTICALS, INC. | ||||||||||||||
| Date: September 11, 2020 | By: | /s/ Derek Meisner | ||||||||||||
| Derek Meisner | ||||||||||||||
| General Counsel | ||||||||||||||